522-00-9

Basic information

• Product Name: ETHOPROPAZINE
• Synonyms: (+-)-profenamine;10-(2-(diethylamino)propyl)-phenothiazin;10-[2-(Diethylamino)-1-Propyl]phenothiazine;10-[2-(Diethylamino)-2-methylethyl]phenothiazine;10H-Phenothiazine-10-ethanamine, N,N-diethyl-alpha-methyl-;2-diethylamino-1-propyl-n-dibenzoparathiazine;Aethopropropazin;Athapropazine
• CAS NO: 522-00-9
• Molecular Formula: C₁₉H₂₄N₂S
• Molecular Weight: 312.47226
• EINECS: 208-320-4
• Product Categories: PARSIDOL
• Mol File: 522-00-9.mol
• Article Data: 3

Chemical Properties

• Melting Point: 53-55°
• Boiling Point: 430.1°Cat760mmHg
• Flash Point: 213.9°C
• Appearance: /
• Density: 1.1070 (rough estimate)
• Refractive Index: 1.5800 (estimate)
• Storage Temp.: -20°C
• CAS DataBase Reference: ETHOPROPAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHOPROPAZINE(522-00-9)
• EPA Substance Registry System: ETHOPROPAZINE(522-00-9)

Safety Data

• Hazardous Substances Data: 522-00-9(Hazardous Substances Data)

Usage

Uses

antiparkinsonian, anticholinergic

Definition

ChEBI: A member of the class of phenothiazines that is phenothiazine in which the hydrogen attached to the nitrogen is substituted by a 2-(diethylamino)propyl group. An antimuscarinic, it is used as the hydrochloride for the symptomatic treatment of Parkinson's d sease.

Safety Profile

Poison by ingestion, subcutaneous, and intravenous routes. An anticholinergic agent used to treat Parkinson's dsease. When heated to decomposition it emits very toxic fumes of NOx and SOx.

InChI:InChI=1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3

Upstream product

• 92-84-2 10H-phenothiazine 
• 761-21-7 1-diethylamino-2-chloropropane 
• 917-64-6 methyl magnesium iodide 
• 122-39-4 diphenylamine 
• 1094-08-2 ethopropazine hydrochloride 
• 522-00-9 10-(2-diethylaminopropyl)phenothiazine 

Downstream Products

• 522-00-9 ethopropazine cation radical 

Relevant articles and documents

CONTROLLED RELEASE COMPOSITIONS AND METHODS FOR USING SAME

Pharmaceutical preparations adapted for mucosal delivery, preferably for nasal delivery, which can be easily and safely used over days to weeks with minimal side effects. The pharmaceutical preparations comprise microcapsules comprising at least one pharmaceutically active agent. The microcapsules provide controlled release of the pharmaceutically active agent. Cytotoxicity is avoided for cytotoxic pharmaceutically active agents and/or for cytotoxic dosages by one or more of the following: (a) manipulating the mucosal transport rate of the pharmaceutically active agent through the mucosal bodies to achieve a transport rate which is substantially the same as the controlled release rate, and/or (b) selecting only a most active and/or less cytotoxic enantiomer of the pharmaceutically active agent for use in the pharmaceutical preparation.

Stability of some phenothiazine free radicals.

-